GlobeNewswire 9/19/2016 Lanthio Pharma Expands Management Team
GlobeNewswire 9/12/2016 MorphoSys Appoints Four R&D Experts to its Newly Formed Scientific Advisory Board
GlobeNewswire 9/6/2016 MorphoSys Initiates Phase 2/3 Trial of CD19 Antibody MOR208 plus Bendamustine in Patients with Relap...
GlobeNewswire 8/29/2016 MorphoSys to Present at Upcoming Investor Conferences
GlobeNewswire 8/3/2016 MorphoSys Successfully Completes Safety Run-in of MOR208 in L-MIND Combination Study in Patients wit...
GlobeNewswire 8/1/2016 MorphoSys AG Reports Results for the First Six Months of 2016
GlobeNewswire 7/25/2016 MorphoSys to Host Q2 2016 Conference Call on August 1, 2016
GlobeNewswire 7/4/2016 MorphoSys Receives Clinical Milestone for Start of Phase 1 Trial in Prevention of Thrombosis with No...
GlobeNewswire 6/17/2016 MorphoSys Reports Publication of Clinical Case Report of a Blood Cancer (DLBCL) Patient Showing Long...
GlobeNewswire 6/6/2016 MorphoSys Presents Updated Clinical Data for MOR202 in Multiple Myeloma and for MOR208 in Non-Hodgki...
GlobeNewswire 6/2/2016 MorphoSys AG Reports Outcome of Annual General Meeting 2016
GlobeNewswire 6/1/2016 MorphoSys to Present at Six Upcoming Conferences
GlobeNewswire 5/24/2016 MorphoSys and MD Anderson Cancer Center Join Forces for the Development of Novel Oncology Therapeuti...
GlobeNewswire 5/19/2016 MorphoSys to Present Clinical Trial Data on Proprietary Programs at Upcoming ASCO Annual Meeting 201...
GlobeNewswire 5/4/2016 MorphoSys to Present at Three Upcoming Conferences
GlobeNewswire 5/3/2016 MorphoSys AG Reports Results for the First Three Months of 2016
GlobeNewswire 4/27/2016 MorphoSys to Host Q1 2016 Conference Call on May 3, 2016
GlobeNewswire 4/21/2016 MorphoSys AG : MorphoSys Provides Update on Results From Partner's Phase 2b/3 RESILIENT Study of Bim...
GlobeNewswire 4/21/2016 Ad hoc: MorphoSys Provides Update on Results From Partner's Phase 2b/3 RESILIENT Study of Bimagrumab
GlobeNewswire 4/18/2016 MorphoSys Licensing Partner GSK Starts Phase 2 Study with GSK3196165 (MOR103) in Hand Osteoarthritis
GlobeNewswire 4/7/2016 MorphoSys and Galapagos Initiate Phase 1 Study in Joint Antibody Program MOR106
GlobeNewswire 4/6/2016 MorphoSys Initiates Phase 2 Combination Trial of MOR208 and Lenalidomide in Patients with Relapsed o...
GlobeNewswire 4/4/2016 Ad hoc: MorphoSys Sues Janssen Biotech and Genmab for Patent Infringement
GlobeNewswire 3/9/2016 MorphoSys to Present at Upcoming Investor Conferences
GlobeNewswire 3/2/2016 MorphoSys AG Reports Results for Fiscal Year 2015